Almost all tumors have varying degrees of metabolic changes during the tumorigenesis and development, which are collectively referred to as metabolic reprogramming. Metabolic reprogramming leads to a large difference in the metabolic patterns of glucose, glutamine, fatty acids and other substances in tumor cells, and is also considered to be an important biomarker of cancer. Many studies have confirmed that metabolic reprogramming provides sufficient energy and material basis for the growth of tumor cells, and has a positive impact on the biological behavior of tumor cells. It also has metabolic reprogramming in the occurrence and development of bladder cancer, which plays an important role in maintaining the growth of tumor cells and enhancing the chemoresistance of bladder cancer. Therefore, to explore the correlation between metabolic reprogramming and bladder cancer and its potential mechanisms, to explore specific drug targets and effective interventions, may provide a groundbreaking idea for the prevention and treatment of bladder cancer.

Metabolic reprogramming; Glycolysis; Bladder cancer; Targeted therapy